Contacts

Convening of the General Assembly: Proposal for the appointment of Elisabeth Kogan to the Supervisory Board

November 9, 2020

General Meeting held in closed session at 5pm CET on December 15, 2020 

Shareholders are asked to give their assent to the appointment of Elisabeth Kogan to the Supervisory Board of MedinCell

Elisabeth Kogan is currently CEO of Clexio Biosciences, she co-founded in 2018

She has held senior executive leadership roles at Teva Phamarceuticals between 2002 and 2018:
• Senior Vice-President of InnoTech, a Specialty R&D unit, in charge of developing new therapeutic entities and innovative technologies
• SVP Global Generic R&D, responsible for developing the company’s global generic pipeline
• VP Global Sales & Marketing, API Division

An introduction video conference will be held on December 1st, 2020 at 6:30pm

Session en français

Mardi 19 décembre, 18h30 : Présentation des résultats du premier semestre de l'année fiscale 2023-24

English session

Tuesday, December 19, 6:30 pm: Half-year earnings call (April 1st - September 30th)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.